RAPH Raphael Pharmaceutical Inc.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1415397 · Fiscal year ends 12/31
Financial factors as of 2026-06-30 (2026Q2), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY33.4%
TTM EPS YoY-37.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-5,297.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets27,028.6%
Debt / equity—
Current ratio0.00x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.02x
Accruals ratio-5,216.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 | 2024Q32024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $40,000 | $37,000 | $345,000 | $73,000 | $141,000 | $72,000 | $211,000 | $162,000 |
| SG&A expense | $159,000 | $186,000 | -$91,000 | $178,000 | $174,000 | $353,000 | $183,000 | $157,000 |
| Operating income | -$199,000 | -$223,000 | -$254,000 | -$251,000 | -$315,000 | -$425,000 | -$394,000 | -$319,000 |
| Interest expense | — | $3,000 | — | — | — | — | — | — |
| Net income | -$223,000 | -$229,000 | -$273,000 | -$255,000 | -$322,000 | -$429,000 | -$395,000 | -$326,000 |
| EPS (basic) | 0.01 | 0.01 | — | 0.01 | 0.02 | 0.02 | — | 0.01 |
| EPS (diluted) | 0.01 | 0.01 | — | 0.01 | 0.02 | 0.02 | — | 0.01 |
| Weighted avg. shares (diluted) | 20.18M | 20.18M | — | 19.63M | 19.63M | 19.63M | — | 18.70M |
| Balance sheet | ||||||||
| Cash & equivalents | $1,000 | $1,000 | $45,000 | $3,000 | $20,000 | $50,000 | $19,000 | $40,000 |
| Receivables | — | — | $2,000 | — | — | — | $2,000 | — |
| Current assets | $6,000 | $1,000 | $51,000 | $5,000 | $28,000 | $91,000 | $25,000 | $49,000 |
| PP&E, net | $1,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 | $2,000 |
| Total assets | $7,000 | $3,000 | $53,000 | $7,000 | $30,000 | $93,000 | $27,000 | $51,000 |
| Current liabilities | $1.89M | $1.67M | $1.49M | $1.27M | $1.08M | $827,000 | $769,000 | $667,000 |
| Short-term debt | — | — | — | — | — | — | $41,000 | — |
| Total liabilities | $1.89M | $1.67M | $1.49M | $1.27M | $1.08M | $827,000 | $769,000 | $667,000 |
| Shareholders' equity | -$1.89M | -$1.66M | -$1.43M | -$1.26M | -$1.05M | -$734,000 | -$742,000 | -$616,000 |
| Shares outstanding | 20.18M | 20.18M | 20.18M | 19.63M | 19.63M | 19.63M | 18.70M | 18.70M |
| Cash flow statement | ||||||||
| Operating cash flow | $0 | -$44,000 | $46,000 | -$17,000 | -$30,000 | -$209,000 | -$62,000 | -$80,000 |
| Financing cash flow | — | — | -$4,000 | $0 | $0 | $240,000 | $41,000 | $0 |
| Stock-based compensation | — | — | $1,000 | $39,000 | $8,000 | $197,000 | $289,000 | $0 |
Free plan shows the latest 8 periods; Pro shows all 24 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.